Postech Research and Business Development Foundation

The Catholic University of Korea Industry-academic Cooperation Foundation

Catholic University Industry Academic Cooperation Foundation

Bifido Co., Ltd.

The Catholic University of Korea

Seung Ki Kwok

Sang Jun Park

Ji Won Kim

Sung Hwan Park

Sun Woo Park

Sung Won Kim

Yun Ju Jeong

Mi La Cho

Geun Eog Ji

Jung Yeon Lim

Ji Hyeon Ju

Jun Geol Ryu

Jae Seon Lee

Seon Yeong Lee

Joo Yeon Jhun

Hyon Ha Lee

Jae Yoon Ryu

Joo Ha Lee

Jeong Ho Chun

Seungchul Lee

Jaeseon Lee

Gyu Won Kim

Su Young Yang

Do Hyun Kim

The present disclosure relates to a cell selection apparatus and method and, in particular, may provide an apparatus that classifies cells by using artificial intelligence, on the basis of the homogeneity of cells from an image pre-processed from image data obtained by capturing images of cells, and marks parts that have an important influence on the classification results, thereby increasing the accuracy of cell selection. In addition, a reliable selection basis can be provided by visualizing the basis for cell selection.

Cell selection apparatus and method

The present invention relates to a pharmaceutical composition for preventing or treating rheumatoid arthritis, and a stem cell therapeutic agent for treating rheumatoid arthritis, comprising nasal inferior turbinate-derived mesenchymal stem cells as an active ingredient. Nasal inferior turbinate-derived mesenchymal stem cells of the present invention have the effects of reducing the production of interleukin-17A (IL-17A), tumor necrosis factor-&#x3b1; (TNF-&#x3b1;), immunoglobulin G2 (IgG2a) which is an inflammation-inducing factor, and/or the proliferative ability of lymph node T cells, increasing interleukin-10 (IL-10) and/or regulatory T-cells (Treg, CD4CD25foxp3cell) that contribute to immune tolerance in spleen cells, and inhibiting the proliferation of human T-cells. The nasal inferior turbinate-derived mesenchymal stem cells have a safer acquisition process than existing mesenchymal stem cells and can be acquired in sufficient amounts within a desired period of time, thus allowing mesenchymal stem cells to be acquired at low cost and high efficiency. Moreover, since the nasal inferior turbinate-derived mesenchymal stem cells have the same genetic origin as individuals administered therewith there are few side effects, the nasal inferior turbinate-derived mesenchymal stem cells can be usefully used for preventing or treating in individually tailored immunocompatible rheumatoid arthritis.

Pharmaceutical composition for preventing or treating rheumatoid arthritis comprising nasal inferior turbinate-derived mesenchymal stem cells as an active ingredient

Disclosed are a novelRAPO (Accession No.: KCTC 13773BP) and a composition for alleviating, treating or preventing rheumatoid arthritis containingRAPO (Accession No.: KCTC 13773BP) selected herein.

RAPO strain for alleviating, treating or preventing rheumatoid arthritis and composition containing the same

Growing community of inventors

Seoul, South Korea

Seung Ki Kwok